Datavault AI Inc. (NASDAQ: DVLT) announced an expansion of its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS), extending its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement is intended to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments. The move draws on a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring.

Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions. Those shares will replace the preferred shares originally contemplated for tax optimization purposes. According to the companies, the agreement is designed to accelerate deployment of Datavault AI’s technology into the healthcare sector and target opportunities in the global health and wellness market while enabling new patient-controlled data transaction models.

The expansion comes as healthcare continues to adopt blockchain and AI technologies to address data interoperability, security, and patient ownership issues. By integrating Datavault AI’s platform, which includes Web 3.0 capabilities for asset valuation and monetization, DataMEDS aims to create a system in which patients can control and potentially profit from their health data. The technology also supports real-world asset tokenization, which could allow patients to tokenize health-related assets such as medical records or wearable device data. In a sector where digital records, remote monitoring, and connected devices generate more data streams, interoperability and governance remain central issues for providers, patients, and technology vendors alike.

Datavault AI said its platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, and energy. The company’s Information Data Exchange enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, which it says supports responsible AI with integrity. The technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring.

The global health and wellness market, including digital health solutions, is projected to grow significantly, driven by increased consumer focus on health and the adoption of wearable devices and remote monitoring. Datavault AI’s expansion into this sector positions the company to participate in those trends, particularly as patients seek greater control over their health data. The partnership with DataMEDS, which specializes in AI and blockchain for healthcare, provides a direct channel for deployment.

For more information on the full press release, visit Additional updates on Datavault AI are available in the company’s newsroom at